P2176
Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on ObesityEffects of a Complete Diet in Critically Ill Patients With Stress HyperglycemiaOrlistat/Phentermine Versus Placebo/PhentermineLong-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or WithdrawalClinical Evaluation of a Normoproteic DietClinical Evaluation of a Specific Enteral Diet for DiabeticsEnteral Nutrition Product in Mild Acute PancreatitisEffect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)A Phase IV Safety and Efficacy of VI-0521 in Obese AdolescentsLifestyle Modification and LiraglutideA Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in OverweiEffects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese ParticipantsTopiramate-Phentermine Combinations for Cocaine DependenceEffect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy SubjectsA Toolbox Approach to Obesity Treatment in Primary CareThe Effect of Phentermine and B12 on Weight Loss Among Obese PatientsEvaluation of a Diet in Patients With Senile DementiaA Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)Phentermine/Gastric Band Weight Loss StudyA Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal ImpairmentA Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic ImpairmentA VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic AdultsEffectiveness and Tolerability of Phentermine in Patients Under Bariatric SurgeryIndividualized Obesity PharmacotherapyFDA Approved Medication to Reduce Binge Eating and/or PurgingQsymia as an Adjunct to Surgical Therapy in the SuperobesePeripheral Pharmacodynamics of Phentermine-Topiramate in Obese PatientsA Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsStudy of VI-0521 Compared to Placebo in Treatment of Obesity in AdultsPharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese AdultsA Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese SubjectsPhentermine/Topiramate Extended Release in Binge Eating Disorder (BED)Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant UsersCardiovascular System in Obesity: Effect of TreatmentSMART Use of Medication for the Treatment of Adolescent Severe ObesityStudying the Effects of Phentermine on Eating BehaviorA Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese AdolescentsDAPA, EQW, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
P4844
Q61957765-6D4F12D8-7F02-474E-B185-932260B29D00Q61975350-6134EA0F-C510-4D7D-93F4-93BF837CF6F3Q63340893-4716E851-01A1-4F96-B086-6386F406EDD8Q63597276-906D8A21-84B7-4463-A7AF-B8CCC12AB57DQ63807143-795B6148-24A3-4677-8406-788E016FEB00Q63813973-CF24B1B4-8786-4833-859A-894FFECF0712Q63815555-E23D4144-819A-439A-819D-CD4BFDF43876Q63819089-E5C16ABF-2331-4906-8C41-E3BDDF61F811Q63842784-E78FDFB0-F2E7-4958-8323-3BB78A3E02F3Q64187830-154EA9B9-C587-48B9-973C-61FCAF566685Q64189860-F1C51DBB-6D51-4929-B592-ED6C3A921584Q64351959-246FB5D0-4C0D-450D-8D8B-E23671716A85Q64601984-50A9FBDB-778E-4E11-A5FC-530B8B012D7CQ64602458-15EC6E4B-D622-4100-906B-98E0F7400D1AQ64606721-1D17FBDE-B728-4E42-8A41-A9440C80299FQ64622012-F8BDD0F6-8DEF-40D7-B696-F26E79FDF853Q64638745-33F0F16C-780E-45F4-93A1-92BCACEC741EQ64652494-77E476E6-029A-44F0-BA01-B70DF9ED65A5Q64693698-47F5373B-F03C-442F-8C73-2C32FA93D89EQ64709414-FD01D0FE-9348-4B7A-A3C9-E01419CF44FDQ64715592-98B2D0F1-1759-4840-8B84-65566882E445Q64716217-08D95065-D776-40ED-B23A-4AF10AF5CE40Q64716251-FA03E955-3E54-48CE-899E-50FCF7F4A923Q64723795-9EFCCFA9-6DCA-44F1-90F2-C728F53E079EQ64793772-54434BC2-5B6B-4259-9934-A1CA065DF7CDQ64805713-C10FEF61-1CB7-46A6-9A5E-6D0C5CC47557Q65331525-CC681289-E395-496A-95FD-AADC742B8DFFQ65351160-5895D127-84B5-458C-AD7C-1A1025387A49Q65367883-4E2EE7A9-4C55-4307-BB7E-413498E12180Q65379305-E9DEEEF5-48CD-4371-A56B-3294572AF916Q65380779-7BE73D9F-7184-4A4E-8336-51C8B8C7B163Q65383003-268F3A22-397F-4EBF-8B83-6F8B7D416FB9Q65385693-FC13CB9F-7FDD-4C68-809D-5ECE6283102CQ65466112-A208BBED-9578-42B0-AF61-80F2ABB38F02Q66044106-2A93B526-2770-4501-BFFB-AB9914B4D9B8Q66061812-F587775D-CBA8-4487-A601-4DA85FD52E09Q66063459-0B88A901-A35D-43C0-9E77-CEBD0F88E7E1Q66344225-3104D6EE-8644-4228-9B55-B0E292AEB646Q66408425-7091D94E-45A1-4429-93DD-66C10F677621Q66409985-7CEE4B4C-5171-4D8F-AA87-6C2A69D4098A
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Fentermiini
@fi
Fentermin
@cs
Fentermin
@hr
Fentermin
@sh
Fentermin
@sr
Fentermin
@sv
Fentermina
@es
Phentermin
@de
Phentermine
@nl
Phentermine
@vi
type
label
Fentermiini
@fi
Fentermin
@cs
Fentermin
@hr
Fentermin
@sh
Fentermin
@sr
Fentermin
@sv
Fentermina
@es
Phentermin
@de
Phentermine
@nl
Phentermine
@vi
altLabel
122-09-8
@fr
2-metylamfetamin
@sv
Adipex-P®
@cy
Adipex-P®
@en
Fentermina
@cy
Fentermina
@en
Ionamin®
@cy
Ionamin®
@en
Mirapront
@sv
Phentermine resin
@en
prefLabel
Fentermiini
@fi
Fentermin
@cs
Fentermin
@hr
Fentermin
@sh
Fentermin
@sr
Fentermin
@sv
Fentermina
@es
Phentermin
@de
Phentermine
@nl
Phentermine
@vi